Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion
Open Access
- 24 December 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (5), 594-595
- https://doi.org/10.1093/rheumatology/kep027
Abstract
Sir, Antibodies to signal recognition particles (SRPs), cytoplasmic proteins involved in the recognition and targeting of signals to the endoplasmic reticulum, were first reported in association with polymyositis (PM) in a 50-year-old woman by Reeves et al. in 1986 [1]. We present our experience of the difficulty in treating two patients with anti-SRP-positive myopathy.Keywords
This publication has 7 references indexed in Scilit:
- Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP)Neuromuscular Disorders, 2006
- Anti-signal recognition particle autoantibodies: marker of a necrotising myopathyAnnals Of The Rheumatic Diseases, 2006
- Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stagesArthritis Research & Therapy, 2006
- Rituximab in the treatment of dermatomyositis: An open‐label pilot studyArthritis & Rheumatism, 2005
- Anti–signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathyArthritis & Rheumatism, 2004
- Myopathy with antibodies to the signal recognition particle: clinical and pathological featuresJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Human autoantibodies reactive with the signal-recognition particle.Proceedings of the National Academy of Sciences, 1986